David Guerrero Setas-rekin lankidetzan egindako argitalpenak (8)

2021

  1. A dna methylation-based gene signature can predict triple-negative breast cancer diagnosis

    Biomedicines, Vol. 9, Núm. 10

  2. Understanding the molecular mechanism of mir-877-3p could provide potential biomarkers and therapeutic targets in squamous cell carcinoma of the cervix

    Cancers, Vol. 13, Núm. 7

2020

  1. ADAM12 is a potential therapeutic target regulated by hypomethylation in triple-negative breast cancer

    International Journal of Molecular Sciences, Vol. 21, Núm. 3

  2. Absence of nuclear p16 is a diagnostic and independent prognostic biomarker in squamous cell carcinoma of the cervix

    International Journal of Molecular Sciences, Vol. 21, Núm. 6

2017

  1. CDH22 hypermethylation is an independent prognostic biomarker in breast cancer

    Clinical Epigenetics, Vol. 9, Núm. 1

  2. CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer

    Oncotarget, Vol. 8, Núm. 9, pp. 15789-15801

2016

  1. Gene promoter hypermethylation is found in sentinel lymph nodes of breast cancer patients, in samples identified as positive by one-step nucleic acid amplification of cytokeratin 19 mRNA

    Virchows Archiv, Vol. 469, Núm. 1, pp. 51-59

2015

  1. Differential role of gene hypermethylation in adenocarcinomas, squamous cell carcinomas and cervical intraepithelial lesions of the uterine cervix

    Pathology International, Vol. 65, Núm. 9, pp. 476-485